Yoshiko Sakuma joined Mitsubishi Gas Chemical in 2008. She belonged to a biological research team, including research on pharmaceutical antibodies, as a quality control engineer, focusing on optimisation and manufacturing, until 2015, and then was part of a safety test team until 2019. Her current responsibilities include evaluating OXYCAPT using commercially available drugs at an MGC laboratory in Kanagawa prefecture in Japan.